Page 101 - Read Online

Owusu Obeng et al. J Transl Genet Genom 2021;5:64-79 I http://dx.doi.org/10.20517/jtgg.2020.52 Page 79

64. Fernando H, Bassler N, Habersberger J, et al. Randomized double-blind placebo-controlled crossover study to determine the effects of
esomeprazole on inhibition of platelet function by clopidogrel. J Thromb Haemost 2011;9:1582-9.
65. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin
Pharmacol Ther 2008;84:326-31.
66. Klein TE, Altman RB, Eriksson N, et al; International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with
clinical and pharmacogenetic data. N Engl J Med 2009;360:753-64.
67. Gardin A, Ufer M, Legangneux E, et al. Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod
Pharmacokinetics in Healthy Subjects. Clin Pharmacokinet 2019;58:349-61.
68. Jin Y, Borell H, Gardin A, Ufer M, Huth F, Camenisch G. In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic
polymorphism impact on siponimod metabolism and pharmacokinetics. Eur J Clin Pharmacol 2018;74:455-64.
69. Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing
Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther 2019;105:1095-105.
70. Yang JJ, Lim JY, Huang J, et al. The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with
cancer. Clin Pharmacol Ther 2013;94:252-9.
71. Cheung ST, Allan RN. Mistaken identity: misclassification of TPMT phenotype following blood transfusion. Eur J Gastroenterol Hepatol
2003;15:1245-7.
72. Kroon LA. Drug interactions with smoking. Am J Health Syst Pharm 2007;64:1917-21.
73. Kato H, Usui M, Muraki Y, et al. Intravenous Administration of Tacrolimus Stabilizes Control of Blood Concentration Regardless of
CYP3A5 Polymorphism in Living Donor Liver Transplantation: Comparison of Intravenous Infusion and Oral Administration in Early
Postoperative Period. Transplant Proc 2018;50:2684-9.
74. Fleming JN, Posadas Salas MA, Taber DJ. Dosing Requirements of Extended-Release Tacrolimus (Astagraf XL) in African American
Kidney Transplant Recipients Converted from Immediate-Release Tacrolimus (AAAKTRS). Ther Drug Monit 2020;42:415-20.
75. Hines RN. Ontogeny of human hepatic cytochromes P450. J Biochem Mol Toxicol 2007;21:169-75.
76. Helldén A, Madadi P. Pregnancy and pharmacogenomics in the context of drug metabolism and response. Pharmacogenomics
2013;14:1779-91.
77. Betcher HK, George AL Jr. Pharmacogenomics in pregnancy. Semin Perinatol 2020;44:151222.
78. Koren G, Ornoy A. Clinical implications of selective serotonin reuptake inhibitors-selective serotonin norepinephrine reuptake inhibitors
pharmacogenetics during pregnancy and lactation. Pharmacogenomics 2018;19:1139-45.
79. Bell GC, Caudle KE, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6
genotype and use of ondansetron and tropisetron. Clin Pharmacol Ther 2017;102:213-8.
80. Tracy TS, Venkataramanan R, Glover DD, Caritis SN; National Institute for Child Health and Human Development Network of Maternal-
Fetal-Medicine Units. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Am J Obstet
Gynecol 2005;192:633-9.